Incannex engages Eurofins to manufacture CannQuit-N, CannQuit-O

Incannex Healthcare (IXHL) engaged multinational contract development and manufacturing organisation Eurofins Scientific (ERFSF) to manufacture Incannex’s two distinct medicated chewable products designed to treat nicotine and opioid addiction disorders. The CannQuit products are combination drug assets with associated granted patents and patent applications that were transferred to Incannex as a result of the acquisition of APIRx Pharmaceuticals, completed in August of 2022. Eurofins will undertake formulation development and manufacture of CannQuit Nicotine and CannQuit Opioid.